This is a paragraph from the Kinetic Securities Research report compiled in May, I was unable to view the recent Alpha Securities report with the link posted on this forum. Could someone please post a link/copy thanks in advance. The recent research reports should be a good guide because the company payed for them and they have been used to promote the company so they should be close to the mark imo.
""Dendreon was confident enough to say that Provenge "significantly prolongs survival".
It would appear that the result is the validation sought for many years by immunotherapy
developers that cancer vaccines not only stabilize disease but increase survival. This is very
bullish for Prima. Prima has to its advantage Orphan Drug Designation for ovarian cancer
which means it will be fast tracked through the FDA and have a 7 year patent extension in US
and 10 year patent extension in Europe.""
http://www.primabiomed.com.au/projects/prodDocuments/Kinectics%20PRR%20Research.pdf
what would good news look like?, page-12
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.5¢ | 28.5¢ | $469.8K | 1.579M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 297652 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 7500 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |